MIRA Pharmaceuticals Announces Positive Proof-of-Concept Results for SKNY-1

Article summary

MIRA Pharmaceuticals reported positive results from an exploratory pilot study of its investigational obesity drug candidate, SKNY-1, in a diet-induced obesity mouse model.